Related Experiment Video

Updated: Aug 20, 2026

Interictal High Frequency Oscillations Detected with Simultaneous Magnetoencephalography and Electroencephalography as Biomarker of Pediatric Epilepsy
10:22

Interictal High Frequency Oscillations Detected with Simultaneous Magnetoencephalography and Electroencephalography as Biomarker of Pediatric Epilepsy

Published on: December 6, 2016

Valproic acid clearance in children with epilepsy

A Sánchez-Alcaraz1, M B Quintana, E López

  • 1Department of Pharmacy, Arnau de Vilanova Hospital, Valencia, Spain.

Journal of Clinical Pharmacy and Therapeutics
|October 2, 1998
PubMed

Insights

Valproic acid (VPA) dosing in children with epilepsy needs age-specific adjustments. Clearance decreases with age, requiring careful pharmacokinetic monitoring for optimal VPA monotherapy.

Area of Science:

  • Pediatric Pharmacology
  • Clinical Pharmacy
  • Epileptology

Background:

  • Valproic acid (VPA) is a widely used antiepileptic drug in children.
  • Understanding VPA pharmacokinetics in pediatric populations is crucial for effective treatment.
  • Age-related differences in drug metabolism can significantly impact VPA dosing and efficacy.

Purpose of the Study:

  • To investigate the population pharmacokinetics of VPA in children with epilepsy.
  • To establish the relationship between VPA plasma concentration and daily dose in pediatric patients.
  • To develop an age-based model for VPA dosage adjustments in monotherapy.

Main Methods:

  • Population pharmacokinetic analysis of 151 VPA plasma levels from 62 children (8 months to 6 years).
  • Children were on VPA monotherapy.
  • Analysis focused on steady-state VPA levels and daily doses.

Main Results:

  • The VPA level:dose ratio increased with age, indicating reduced clearance in older children.
  • Weight-adjusted VPA clearance (Cl) decreased significantly with increasing age.
  • A predictive equation (Cl = 47.6 x age(months)^-0.29) was derived for estimating VPA clearance based on age (8-72 months).

Conclusions:

  • The established relationship between VPA clearance and age is vital for optimizing VPA monotherapy in children.
  • This pharmacokinetic model can guide the initial maintenance dose selection for pediatric VPA treatment.
  • Age-specific pharmacokinetic profiling enhances the safety and efficacy of VPA in pediatric epilepsy management.
Abstract

More Related Videos

Sampling Cerebrospinal Fluid and Blood from Lateral Tail Vein in Rats During EEG Recordings10:46

Sampling Cerebrospinal Fluid and Blood from Lateral Tail Vein in Rats During EEG Recordings

Published on: September 1, 2023

Electromagnetic Source Imaging in Presurgical Evaluation of Children with Drug-Resistant Epilepsy09:57

Electromagnetic Source Imaging in Presurgical Evaluation of Children with Drug-Resistant Epilepsy

Published on: September 20, 2024

Related Concept Videos

Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance01:23

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...